Guggenheim Raises AstraZeneca Price Target Ahead of Q1 Earnings

Core Viewpoint - Guggenheim has raised its price target for AstraZeneca to 16,500 GBp ahead of the company's Q1 earnings report, reflecting confidence in its oncology growth and pipeline potential [2][6][7]. Group 1: Financial Performance - AstraZeneca reported FY2025 revenue of $58.74 billion, an 8% increase at constant exchange rates (CER) [2][7]. - The oncology segment revenue grew by 17% CER to $25.618 billion, driven by Tagrisso at $7.254 billion and Enhertu at $2.775 billion, which saw a 40% increase CER [2][13]. - The company has a current market cap of approximately $292.1 billion with 1.55 billion shares outstanding [9]. Group 2: Growth Drivers - AstraZeneca's pipeline includes over 20 Phase 3 trial readouts expected in 2026, with 16 positive Phase 3 readouts and 43 regulatory approvals recorded in 2025 [3][13]. - The company has increased its dividend to $3.30 per share for 2026 and is committing to a $15 billion investment in China through 2030, indicating strong management confidence in long-term growth [3][13]. Group 3: Analyst Sentiment - Guggenheim's analyst Seamus Fernandez maintains a Buy rating, with the firm's price target reflecting an optimistic outlook compared to the consensus price target of $208.54 among Wall Street analysts [6][7]. - The upgrade is based on AstraZeneca's execution track record and the potential for multiple expansion if core EPS growth accelerates as guided [9][10].